Nagai Y, Ohsawa K, Ieki Y, Kobayashi K
First Department of Internal Medicine, School of Medicine, Kanazawa University, Japan.
Endocr J. 1996 Oct;43(5):545-9. doi: 10.1507/endocrj.43.545.
The effect of interferon-beta (IFN-beta) on thyroid function was studied in patients with chronic hepatitis who had no preexisting thyroid disease. Eleven patients (9 males and 2 females) aged 20 to 65 years, with a mean age of 47.7 +/- 13.5 years, were treated with 6 million units of IFN-beta intravenously every day for 8 weeks. During IFN-beta administration (4th to 8th week of treatment), both serum free thyroxine (FT4) and free triiodothyronine (FT3) concentrations decreased significantly (P < 0.0005 and P < 0.05, respectively): FT4, 1.37 +/- 0.17 to 1.09 +/- 0.12 ng/dl, and FT3, 3.71 +/- 0.45 to 3.28 +/- 0.34 pg/ml. On the other hand, serum TSH increased significantly from a baseline of 1.70 +/- 0.82 to 3.34 +/- 1.98 microU/ml during IFN-beta administration (P < 0.005). Four to eight weeks after cessation of treatment, the mean serum FT4 concentration was similar to that during IFN-beta administration (1.04 +/- 0.14 ng/dl), but mean serum FT3 and TSH concentrations returned to pre-treatment levels (FT3, 3.57 +/- 0.42 pg/ml and TSH, 1.60 +/- 0.84 microU/ml). Both reverse T3 and thyroglobulin were essentially unchanged. Tests for anti-thyroglobulin and anti-microsomal antibodies were negative in all the patients. These results indicate that IFN-beta may inhibit thyroid function in patients without preexisting thyroid disease irrespective of humoral immune responses.
在无既往甲状腺疾病的慢性肝炎患者中研究了β-干扰素（IFN-β）对甲状腺功能的影响。11例年龄在20至65岁之间（平均年龄47.7±13.5岁）的患者（9例男性和2例女性），每天静脉注射600万单位IFN-β，共8周。在给予IFN-β期间（治疗第4至8周），血清游离甲状腺素（FT4）和游离三碘甲状腺原氨酸（FT3）浓度均显著下降（分别为P<0.0005和P<0.05）：FT4从1.37±0.17降至1.09±0.12 ng/dl，FT3从3.71±0.45降至3.28±0.34 pg/ml。另一方面，在给予IFN-β期间，血清促甲状腺激素（TSH）从基线的1.70±0.82显著升至3.34±1.98 μU/ml（P<0.005）。治疗停止4至8周后，血清FT4平均浓度与给予IFN-β期间相似（1.04±0.14 ng/dl），但血清FT3和TSH平均浓度恢复到治疗前水平（FT3为3.57±0.42 pg/ml，TSH为1.60±0.84 μU/ml）。反三碘甲状腺原氨酸和甲状腺球蛋白基本未变。所有患者的抗甲状腺球蛋白和抗微粒体抗体检测均为阴性。这些结果表明，IFN-β可能在无既往甲状腺疾病的患者中抑制甲状腺功能，而与体液免疫反应无关。
